Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer

摘要: Two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) have been approved in Canada for the treatment of metastatic colorectal cancer (mCRC) – cetuximab, a mouse-human chimeric MoAb, and panitumumab, fully human MoAb. This paper reviews efficacy anti-EGFR cetuximab panitumumab both as monotherapy combination with cytotoxic chemotherapy mCRC. Both demonstrated clinical patients mCRC, an advantage that has recently found to be limited largely those wild-type KRAS tumors. Advantages using these agents include reduced cost toxicity. While addition irinotecan shown superior progression-free survival response compared monotherapy, there is currently no evidence benefit irinotecan.